June 24: The current negotiating document on disabilities at the WIPO SCCR is SCCR/22/16. A new version Prov. 1 was passed out this morning. Continue Reading
La Oficina del Representante Comercial de los Estados Unidos (USTR) ha declarado su intención de tener completadas sus propuestas sobre protección de la propiedad intelectual a comienzos de la próxima ronda de negociaciones del TPP en Vietnam, del 20 al 24 de junio de 2011. En su rápida agenda, los negociadores del TPP han anunciado que ellos esperan concluir el acuerdo para el encuentro de los miembros del Foro de Cooperación Económica Asia-Pacífico, a realizarse en Hawaii del 8 al 13 de noviembre de 2011. Continue Reading
I have another blog that deals with U.S. employment data from the information sector. This one provides May 2010 employment and wage data from fourteen 4- and 5-digit NAICS industry groups in the “Information Sector.”
Notes on the data
The Office of the U.S. Trade Representative (USTR) has declared an intention to have all its proposals on intellectual property protections by the commencement of the next round of TPP talks in Vietnam June 20-24, 2011. On a fast timetable, TPP negotiators have already announced that they want to finalize TPP by the summit meetings of the members of the Asia-Pacific Economic Cooperation on November 8-13, 2011 in Hawaii. The TPP will impact health, access to knowledge, and without the necessary safeguards, the right to privacy.
Asian Group’s Statement
22nd session of the Standing Committee on Copyright and Related Rights
(15-24 June 2011)1. I have the honour to take the floor on behalf of the Asian Group.
Opening statement of Uruguay at WIPO’s 22nd Standing Committee on Copyright and Related Rights
Comité Permanente de Derechos de Autor y Conexos – SCCR 22 – OMPI – Ginebra
Intervención de la Delegación de Uruguay. Ginebra, 15 de junio de 2011.Gracias Señor Presidente,
Señor Presidente, reciba de nuestra delegación nuestras mas sinceras felicitaciones por su designación como Presidente del Comité Permanente de Derechos de Autor y Conexos SCCR y cuente con nuestro apoyo para hacer una exitosa gestión al frente de este importante comité.
Señor Presidente:
White House and European Commission trade official oppose waiver of drug patents for Least Developed Countries (LDCs)
Draft of the Political Declaration on HIV and AIDS disappoints public health NGOs
FDA New drug approvals for 2011, through June 6
This is a report from the FDA on 2011 new molecular entities (NMEs) approvals, through June 6, 2011. The total number of FDA approvals during that same period was 150. So far, 16 NMEs have been approved in five months, a sharp increase in approvals over the same period 2010.
6 NMEs NDAs were considered priorities
8 NDAs that were considered standard approvals
2 BLA (biologic products) that were not classified.
- NMEs were 10.7 percent of all approvals.
- The NME priority NDAs were 4 percent of FDA approvals.
Senator Sanders introduces two medical innovation prize bills in U.S. Senate to de-link R&D costs from drug prices
On Thursday, May 26, 2011, Senator Bernie Sanders (I-VT) introduced two bills in the United States Senate that would de-link R&D costs from drug prices. The bill names and numbers are as follows: